Sartorius confirms 2025 guidance

Sartorius confirms 2025 guidance

Title: Sartorius Stedim Biotech Confirms 2025 Guidance

July 2, 2025 – Sartorius Stedim Biotech SA has confirmed its financial guidance for the year 2025, reporting strong performance during the first half of the year. The company's half-year results, released on July 22, 2025, showed significant growth in both sales revenue and profitability, reflecting a robust market environment for biopharmaceutical solutions.

Sartorius Stedim Biotech's sales revenue for the first half of 2025 reached 1,490 million euros, an increase of 9.4 percent in constant currencies compared to the prior year. This growth was primarily driven by the high-margin recurring business with consumables, which saw a substantial year-over-year gain. The Americas region reported a significant increase of 11.0 percent, while EMEA and the Asia/Pacific regions grew by 8.7 percent and 8.1 percent, respectively [1].

The company's underlying EBITDA margin reached 31.0 percent, up from 28.2 percent in the previous year. This improvement was largely attributed to volume and product mix effects, as well as economies of scale. Underlying net profit increased by 38.3 percent to 228 million euros, while net profit after non-controlling interest surged by 48.2 percent to 154 million euros [1].

Dr. René Fáber, CEO of Sartorius Stedim Biotech, commented on the company's performance: "Our high-margin recurring business with consumables has continued to grow, contributing to a substantially enhanced profitability. Driven by strong underlying customer demand for single-use solutions for bioprocessing, we have seen sales revenue increase across all regions."

The company's balance sheet remains robust, with equity totaling 4,039 million euros and a net debt to underlying EBITDA ratio of 2.7. Management expects organic sales revenue growth of around 7 percent for fiscal 2025, with an underlying EBITDA margin of around 30 to 31 percent. The ratio of capital expenditure to sales revenue is expected to be around 13 percent, and the ratio of net debt to underlying EBITDA is projected to be around 2.5 [1].

Sartorius Stedim Biotech's guidance for fiscal 2025 is based on the strong market performance observed during the first half of the year. The company continues to invest in its global research and production infrastructure, aiming to maintain its leadership position in the biopharmaceutical industry.

References:
[1] https://asiaplustj.info/en/news/world/20250718/putin-orders-restrictions-on-foreign-messaging-apps
[2] https://economictimes.indiatimes.com/news/international/us/whatsapp-in-firing-line-as-russia-prepares-to-hit-back-at-us-with-sanctions-by-banning-metas-messaging-app-aims-to-develop-its-own/articleshow/122776732.cms?from=mdr